Evidence-Based Medicine Guidelines
Single agent versus combination chemotherapy for metastatic breast cancer
Single agent versus combination chemotherapy for metastatic breast cancer is a topic covered in the Evidence-Based Medicine Guidelines.
To view the entire topic, please log in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
There's more to see -- the rest of this entry is available only to subscribers.
Citation
"Single Agent Versus Combination Chemotherapy for Metastatic Breast Cancer." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/454060/all/Single_agent_versus_combination_chemotherapy_for_metastatic_breast_cancer.
Single agent versus combination chemotherapy for metastatic breast cancer. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/454060/all/Single_agent_versus_combination_chemotherapy_for_metastatic_breast_cancer. Accessed May 18, 2022.
Single agent versus combination chemotherapy for metastatic breast cancer. (2019). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. https://evidence.unboundmedicine.com/evidence/view/EBMG/454060/all/Single_agent_versus_combination_chemotherapy_for_metastatic_breast_cancer
Single Agent Versus Combination Chemotherapy for Metastatic Breast Cancer [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2022 May 18]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/454060/all/Single_agent_versus_combination_chemotherapy_for_metastatic_breast_cancer.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Single agent versus combination chemotherapy for metastatic breast cancer
ID - 454060
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/454060/all/Single_agent_versus_combination_chemotherapy_for_metastatic_breast_cancer
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine
ER -
